@article{de Melo Rodrigues_Victor Gottardello Zecchin_Maria Lúcia de Martino Lee_Antonella Adriana Zanette_Adriana Seber_Raul Corrêa Ribeiro_2021, title={Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines: SBTMO/SOPOBE Guidelines: Pediatric AML}, volume={2}, url={https://www.jbmtct.com.br/seer/index.php/jbmtct/article/view/139}, DOI={10.46765/2675-374X.2021v2n4p139}, abstractNote={<p>Acute myeloid leukemia (AML) represents 15%–20% of acute leukemias in children, and the risk of treatment failure is based on genetic risk and response to therapy<sup>1-4</sup>. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity<sup>5</sup>. The best therapeutic results are achieved by integrating intensive chemotherapy, optimal supportive care, and hematopoietic stem cell transplant (HSCT) adapted to each patient’s risk of relapse<sup>6–9</sup>. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML to provide evidence-based guidance for the appropriate management of this disease.</p>}, number={4}, journal={JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY}, author={de Melo Rodrigues, Ana Luiza and Victor Gottardello Zecchin and Maria Lúcia de Martino Lee and Antonella Adriana Zanette and Adriana Seber and Raul Corrêa Ribeiro}, year={2021}, month={Nov.}, pages={139} }